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Abstract
Background: There is good evidence in the literature that the cannabinoid system is disturbed in colorectal cancer. In the
present study, we have investigated whether CB1 receptor immunoreactive intensity (CB1IR intensity) is associated with
disease severity and outcome.
Methodology/Principal Findings: CB1IR was assessed in formalin-fixed, paraffin-embedded specimens collected with a
consecutive intent during primary tumour surgical resection from a series of cases diagnosed with colorectal cancer.
Tumour centre (n=483) and invasive front (n=486) CB1IR was scored from 0 (absent) to 3 (intense staining) and the data
was analysed as a median split i.e. CB1IR ,2 and $2. In microsatellite stable, but not microsatellite instable tumours (as
adjudged on the basis of immunohistochemical determination of four mismatch repair proteins), there was a significant
positive association of the tumour grade with the CB1IR intensity. The difference between the microsatellite stable and
instable tumours for this association of CB1IR was related to the CpG island methylation status of the cases. Cox
proportional hazards regression analyses indicated a significant contribution of CB1IR to disease-specific survival in the
microsatellite stable tumours when adjusting for tumour stage. For the cases with stage II microsatellite stable tumours,
there was a significant effect of both tumour centre and front CB1IR upon disease specific survival. The 5 year probabilities
of event-free survival were: 8565 and 6668%; tumour interior, 8664% and 6368% for the CB1IR,2 and CB1IR$2 groups,
respectively.
Conclusions/Significance: The level of CB1 receptor expression in colorectal cancer is associated with the tumour grade in a
manner dependent upon the degree of CpG hypermethylation. A high CB1IR is indicative of a poorer prognosis in stage II
microsatellite stable tumour patients.
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Introduction
The G-protein coupled cannabinoid1 (CB1) receptors are most
well known for their role in mediating the psychotropic effects
sought after by recreational users of cannabis. However, CB1
receptors and their endogenous ligands anandamide (arachido-
noylethanolamide) and 2-arachidonoylglycerol mediate a multi-
tude of effects in the body including the regulation of pain, bone
formation, energy homeostasis and gastrointestinal function [1–4].
In the human colon, CB1 receptors are found in the crypt
epithelium as well as in subepithelial inflammatory cells, in smooth
muscle of blood vessels and in submucosal plexus [5,6], where they
modulate, among other functions, the rate of intestinal transit and
colonic propulsion [4].
In addition to the functions described above, the endocanna-
binoid system acts as a ‘‘damage limiting’’ system to mitigate the
effects of pathological situations. This appears to be particularly
true for the gastrointestinal endocannabinoid system. Thus,
inflammation induced by agents such as 2,4-dinitrobenzene
sulfonic acid, trinitrobenzene sulfonic acid, mustard oil or dextran
sulfate sodium is more pronounced in CB1
2/2 mice than in their
wild type littermates, whilst treatment with a CB receptor agonist,
or with compounds blocking the cellular removal and metabolism
of endocannabinoids, alleviates the inflammation [7–11]. A CB1
receptor polymorphism (1359 G/A) is associated with a reduced
susceptibility to ulcerative colitis in man [12], although to our
knowledge it is not yet known how this single nucleotide
polymorphism affects cannabinoid signalling. Aberrant crypt foci
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carcinoma sequence in colorectal cancer development, are formed
as a result of azoxymethane treatment in mice, and the treatment
is associated with an increase in the levels of 2-arachidonoylgly-
cerol. Blockade of the metabolism of this endocannabinoid
reduced the incidence of aberrant crypt foci, as did treatment
with a CB receptor agonist [13] and, perhaps surprisingly, by
treatment with a CB1 receptor inverse agonist [14].
Cannabinoids and endocannabinoids produce potentially useful
effects upon cancer cell proliferation, motility and invasive
behaviour (reviews, see [15,16]). In colorectal cancer cell lines,
both CB1-dependent and -independent effects of endogenous and/
or synthetic cannabinoids upon cell viability have been reported
[17–20]. In a genetic model of colorectal cancer progression
(Apc
Min/+ mice), animals lacking the CB1 receptor showed a
greater number of small intestinal and colonic polyps than the
corresponding CB1
+/+ mice [21]. Colorectal cancer patients who
are either homo- or heterozygous for the 1359 G/A CB1 receptor
polymorphism show a shorter survival time than the G/G wild-
type patients [22]. Finally, reduced expression of CB1 receptor
mRNA and protein have been reported in colorectal cancer
[17,21], due at least in part to an increased rate of methylation of
the promotor region of the receptor [21].
The above data are consistent with the suggestion that the
endogenous cannabinoid system may be dysfunctional in colorec-
tal cancer, and that such a dysfunction may affect disease severity
and/or outcome. One way of investigating this possibility is to
determine the level of CB1 receptor expression in a large cohort of
well-characterised cases of colorectal cancer with long follow-up
times. This has been undertaken in the present study. Given that
colorectal cancer is highly heterogeneous, a particular focus has
been made upon the relation of the CB1 immunoreactive
intensities with key pathological/molecular components of the
disease [23]: stage, tumour grade, microsatellite instability
screening status, incidence of buds at the tumour front, and
CpG island methylator phenotype (CIMP).
Methods
Ethics Statement
The research ethical committee at Umea ˚ university hospital
(Regional Ethical Review Board in Umea ˚, Sweden) approved the
handling of tissue samples and patient data in the present study,
including the procedure whereby patients verbally gave their
informed consent. This consent was documented in each patient
record, and this was considered by the ethical committee to be
sufficient. In the database used for the analyses here, the tissue
samples were given a case number and year, and the patient
names were not indicated in the database.
Patients
The formalin-fixed, paraffin-embedded samples used in the
present study were obtained from tissue collected during primary
tumour surgical resection of colorectal cancer (CRUMS (Colo-
rectal cancer in Umea ˚ study)). The samples were collected with a
consecutive intent at the Department of Surgery, Umea ˚ University
Hospital, Sweden, during the period 1995–2003 and where
possible the patients were followed for up to 113 months [24]. In
addition to the clinico-pathological data reported in [24], data on
the microsatellite stability/instability screening status (immuno-
chemical determination of the expression of four mismatch repair
proteins) and CIMP have been collected and previously reported
[25]. Incidence of buds at the tumour front were evaluated as in
[26]. Exclusion criteria were insufficient or unavailable tumor
tissue sample and insufficient clinical information. All in all, 487
cases were scored for either tumour centre or tumour front CB1
receptor immunoreactivity (see below). The clinical information in
the database for these patients was as follows: median age 71 years
(range 26–96, n=487, of which 269 were males and 218 females);
cancer location in right colon 31.1%, left colon 31.1%, rectum
37.8% (n=482); disease stage I 15.5%, II 39.3%, III 21.0%, IV
24.2% (n=476); tumour grade well/well-moderately differentiat-
ed 48.75%, moderate-poor/poorly differentiated 51.25%
(n=480); microsatellite stable 85.0%, microsatellite instable
15.0%; (n=473); CIMP status negative 50.4%, low 37.2%, high
12.4% (n=484). Further, 82.4% (of 483 cases) did not receive
preoperative radiotherapy (either 565G yo r2 5 62 Gy); 75.0% (of
476 cases) had radical surgery; and 13.7% (of 475 cases) received
adjuvant chemotherapy.
Measurement of CB1 receptor immunoreactivity (CB1IR)
in the tumour tissue
The paraffin-embedded tissue sections were deparaffinized and
rehydrated before antigen retrieval in a pressure cooker (2100
retriever, Biocare Medical) in Diva Decloaker (Biocare Medical).
Samples were subsequently placed in a Ventana semiautomated
immunostaining machine (Ventana Medical Systems Inc., Tucson,
AZ). The CB1 receptor antibody (AbCam cat. no. 23703, AbCam
plc, Cambridge, UK, diluted 1:50) and the secondary components
(iVIEW DAB Detection Kit, Ventana Medical Systems Inc.) were
then added. The antibody, a rabbit polyclonal raised to an peptide
corresponding to C terminal amino acids 461–472 of the human
CB1 receptor and which cross-reacts with the human, mouse and
rat CB1 receptor according to data from the manufacturers, has
been shown previously by researchers in Umea ˚ (including the
corresponding author) to produce the appropriate pattern of
staining in human cerebellum, but not to produce immunoreac-
tivity in forebrains from CB1
2/2 mice [27]. An ExPasy Blast
(http://expasy.org/tools/blast/) of the peptide sequence gave CB1
and its two splice variants as the only hits in man. In several other
species, CB1 receptors were again identified, the only non-CB1 hits
being from proteins termed ‘‘Uncharacterized protein [Gene:
CNR1]’’ (from pig, dog and chicken) as well as ‘‘Putative
uncharacterized protein [Gene: PANDA_015085] - Ailuropoda
melanoleuca (Giant panda)’’ and ‘‘Chromosome 14 SCAF15003,
whole genome shotgun sequence fragment’’ in Tetraodon nigroviridis
(Green pufferfish).
CB1IR was assessed by one investigator (SBG) who was blinded
to the clinical status of the patients. The samples were graded on
the basis of the dominant CB1 receptor immunoreactive intensity
(CB1IR) in the tumour interiors and in the tumour invasive fronts
and scored from 0 (absent) to 3 (intense) for the cells. When all
samples had been scored, the investigator repeated the procedure
(without access to the previous scores) and then compared the
scores on the two runs. Cases where the scores were divergent
were then assessed a third time, again without access to the
previous scores. For the tumour front samples scored, for example,
there were 53 occasions where the first and second scores
disagreed, due mainly to erroneous scores from the initial stage
of the first run. The final scores were then entered by another
investigator (CJF) into the database for analysis.
Statistical evaluations
Kaplan-Meier survival analyses, Fisher’s exact test and x
2 tests
were undertaken using the statistical package built into the
GraphPad Prism 5 computer programme for the Macintosh
(GraphPad Software Inc., San Diego, CA, USA). Cox propor-
tional-hazards and binary logistic regression analyses were
CB1 Receptor Immunoreactivity in Colorectal Cancer
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Macintosh (IBM Inc., Somers, NY, USA). For survival analyses,
disease-specific events were defined as death with known
disseminated or recurrent disease (‘‘{ca’’). Death from other causes
was censored, as were the cases where the patient was still alive at
the date of last follow-up. The duration of event-free survival is
defined as the time from diagnosis until either the date of
colorectal cancer death, death of other causes, or if no death
occurred, until the date of last follow-up.
Results
CB1IR immunohistochemistry
Initial studies were undertaken using the same batch of the
antibody as in a previous study by researchers in Umea ˚ using
tissue microarrays from prostate cancer samples [27]. We found
that at a dilution of 1:300, CB1IR was found in the epithelial cells
of the crypts, with scattered positivity in subepithelial inflamma-
tory cells (Fig. S1A), a finding consistent with studies of CB1IR in
the normal colon [5,6]. An example of tumour tissue stained with
this batch is shown in Fig. 1B. Due to limited amounts of antibody
remaining, we used a later batch of the AbCam antibody (batch
761993) for the main study, and found that a lower dilution (1:50)
was required for good immunostaining. An example of staining is
seen in Fig. 1A, with a corresponding serial section without
primary antibody shown in Fig. 1B.
The best specificity test for immunochemistry is considered to
be the use of knockout controls [28]. We found that appropriate
immunochemical staining was seen in the brains of wild-type mice,
whereas this was absent from brains of CB1
2/2mice (Fig. S2).
Ashton [29] has recently argued that optical density histograms
are useful in distinguishing between a change in the pattern of
immunolabelling (as should be seen for a true loss of signalling in a
knockout) compared to a reduction in labelling intensity (which
would raise a question as to the validity of the antibody). Optical
density histograms of our wild-type and CB1
2/2 tissues are clearly
different (best seen for the higher magnification slides, Fig. S2),
consistent with good antibody specificity [29].
A common way of testing for antibody specificity is to
investigate preadsorbtion of the antibody with the immunising
peptide, although the usefulness of this measure has been
questioned [30]. Nevertheless, a series of experiments using
preincubation of the antibody with the immunising peptide
(AbCam, Cat. No. 50542) were also undertaken. However,
preincubation with the immunising peptide greatly increased the
observed immunoreactivity rather than blocked it, and gave a
rather random pattern of immunoreactive staining (data not
shown). The immunising peptide (amino acid sequence
MSVSTDTSAEAL) has two negatively charged amino acids
(aspartate and glutamate), five polar amino acids (three serine, two
threonine) and no positively charged amino acids. It is well known
that negatively charged peptides bind to glass, and we conclude
that the washing procedure in the Ventana technique, while being
sufficient to provide good specificity per se (as seen in the knockout
mice), is not sufficient to remove antibody-bound positive control
peptide adhering non-specifically to glass and/or to zwitterionic
lipids.
Distribution of CB1IR scores in the tumour centre and
fronts
A total of 483 (tumour interior) and 486 (tumour front) cases
were scored for CB1IR intensity and entered into the database.
Both plasma membrane and cytoplasmic CB1IR was scored, so
the values represent the total pool of CB1 receptors. Nuclear
staining of CB1IR (found in 42 cases) was not scored. The
frequency distributions of the CB1IR for the tumour centre and
fronts were similar, with a score of 0 being returned for 77 and 60
cases; a score of 1 for 196 and 185 cases; a score of 2 for 140 and
156 cases; and a score of 3 for 70 and 85 cases (numbers are
tumour centre and fronts, respectively). There was no significant
difference in the distribution pattern of the two sets of scores
(p.0.1, x
2 test). It was noted that the scores for the two regions
were not always the same for a given case. Indeed, for the 482
cases scored for both tumour centre and front, the scores were the
same in only 319 (66%) of the cases, being higher in the tumour
front in 110 (23%) cases and higher in the tumour centre in 53
(11%) cases. In consequence, throughout this study, both tumour
centre and tumour front scores have been analysed separately.
Non-malignant tissue was not scored, but in general its level of
immunoreactivity appeared to be lower rather than higher than
seen for the tumour tissue.
Association of CB1IR with patient characteristics at
surgery
In view of the frequency distribution of the CB1IR, the analyses
were conducted using a simple median split, i.e. CB1IR,2 and
$2. Using the entire data set to search for variables, a binary
logistic regression with parameters gender, site (i.e. right colon, left
colon, rectum), radiotherapy (prior to surgery), disease stage,
Figure 1. CB1 receptor immunoreactivity in tumour samples. Sections from the same case were used in the presence (Panel A) and absence
(Panel B) of the primary antibody. Objective magnification is 106.
doi:10.1371/journal.pone.0023003.g001
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mucinous or non-mucinous), microsatellite instability screening
status [stable (MSS) or instable (MSI)], amount of lymphocytes at
the tumour front and the frequency of tumour buds (small
aggregates of tumour cells at the tumour invasion front, [31]) was
conducted. Of these variables, only the tumour histological grade
(p,0.005) and microsatellite instability screening status (p,0.05)
were significantly associated with the CB1IR (data not shown).
These effects can simply be visualised by dividing the dataset into
four groups on the basis of the two significant parameters (Fig. 2).
The majority of the cases were classified as MSS, and the detailed
CB1IR distributions for the MSS cases who did not receive
radiotherapy prior to surgery are summarised in Table 1. In both
the tumour centre and tumour fronts, there are more cases with a
CB1IR$2 for MSS cases with moderate-poor/poor tumour
differentiation than with well/well-moderately differentiated
tumours. In the MSI cases, this effect of the tumour histological
grade is not seen, and the cases have a similar CB1IR distribution
to the moderate-poor/poorly differentiated MSS cases (Fig. 2).
Further analysis of the 62 cases with MSI scored for CB1IR who
did not receive radiotherapy prior to biopsy revealed no significant
association of the tumour centre or front CB1IR with either disease
stage (here stages I and II were combined since only 4 cases with
stage I were scored for tumour centre CB1IR), tumour grade,
whether the tumours were mucinous or non-mucinous, incidence
of lymphocytes at the tumour front or CIMP status (p.0.1,
Fisher’s exact test or x
2 test, as appropriate, data not shown). For
gender, the p values for the CB1IR distributions were 0.069 and
0.18 for tumour centre and front, respectively (Fisher’s exact test),
and for the incidence of buds at the tumour front, the p values (x
2
test) were 0.086 and 0.073, respectively (data not shown).
One major difference between MSS and MSI is the greater
incidence of a high degree of CpG island methylation in the latter
[32]. In our data set, of the 467 cases scored for microsatellite
instability screening status, CIMP status and tumour centre
CB1IR, the CIMP distributions were: MSS (n=396), negative
225 (57%), low 153 (39%) and high 18 (4.5%); MSI (n=71),
negative 15 (21%), low 17 (24%) and high 39 (55%) (p,0.0001, x
2
test). When the CIMP status of the samples was added into the
binary logistic regression of the whole dataset with the parameters
described above, the significant effect of the tumour histological
grade was retained (p,0.005) for both tumour centre and front
CB1IR, but the effect of the microsatellite instability screening
status was lost for the tumour centres (p.0.1) but not for the
tumour fronts (p,0.05) (data not shown). In order to investigate
this further, the data for the samples was divided into the three
CIMP groups: negative, low and high regardless of microsatellite
instability screening status or whether the patients had received
radiotherapy prior to surgery. There was a clear influence of
CIMP status on the results, where the effect of the tumour
histological grade was seen in the cases with a CIMP-negative
score but not in the cases with a CIMP-high score, the CIMP-low
cases being somewhere in the middle (Fig. 3). This analysis did not
take into account the microsatellite instability screening status of
the cases in order to achieve sufficient group sizes. However, a
similar pattern is seen when the MSS and MSI cases are analysed
separately, although as a caveat it should be pointed out that some
of the group sizes are very small (Fig. S3).
Association of CB1IR with disease outcome
The cases in the database had been followed for up to 113
months [24] allowing the influence of the CB1IR score at diagnosis
upon disease outcome to be determined. Using the entire dataset
(i.e. even those cases where CB1IR was not scored, a univariate
Cox proportional hazards regression analysis on the entire dataset
indicated that the administration of radiotherapy prior to surgery
was, unsurprisingly, associated with disease outcome (Exp(B) 0.60
[95% CI 0.40–0.91] p,0.05) where the number of cases not
receiving/receiving radiotherapy was 441/102. The Cox propor-
tional hazards regression analysis is a test used to determine the
contribution of the parameter(s) under investigation upon disease-
specific survival without making assumptions as to the nature of
Figure 2. Influence of the tumour histological grade and MSI screening status upon CB1IR in colorectal cancer. Panel A, tumour centre;
Panel B, tumour front. The data are grouped according to tumour histological grade (w-m, well/well-moderately differentiated; m-p, moderate-poor/
poorly differentiated) and microsatellite stability (MSS, stable; MSI, instable). The x
2 and hence p values are for the data grouped as a 462 matrix
(where the 2 is the CB1IR). n refers to the total number of cases for each bar.
doi:10.1371/journal.pone.0023003.g002
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hazards ratio, indicates the change in risk as the parameter under
investigation is changed from the default parameter (here no
radiotherapy) to the test parameter (here radiotherapy). In this
case, the radiotherapy reduced the risk of death due to the disease
since the Exp(B) value was significantly lower than unity. In order
to remove the influence of this parameter, the CB1IR data was
analysed only for the cases that did not receive radiotherapy. In
addition, the MSS and MSI cases were analysed separately.
For the MSS cases, a univariate Cox proportional hazards
regression analysis failed to show a significant effect of either
tumour interior or front CB1IR upon disease-specific survival.
However, when a bivariate analysis was undertaken with disease
stage as the second parameter, a highly significant contribution of
CB1IR was seen (Table 2). This was confirmed in Kaplan-Meier
survival plots: for the entire data set, there was no significant
contribution of the tumour interior CB1IR (Fig. 4A), whereas in
tumour stage II (where the tumours have infiltrated the muscularis
propria of the colon or rectum, but have not given rise to lymph
node metastasis), and in tumour stage IV (where the tumours have
spread to other organs), cases with a CB1IR$2 have a poorer
disease-specific survival than cases with a CB1IR,2 (Figs. 4B and
D; definitions of disease staging given in [33]). No difference was
seen for tumour stage III, although it should be borne in mind that
this is a highly heterogenous group, that the number of cases was
smaller than for disease stages II and IV and that subgroup
Table 1. CB1IR in tumour interiors for microsatellite stable (MSS) cancers: correlation with patient characteristics for patients not
receiving radiotherapy prior to surgery.
Tumour centre Tumour front
Parameter n CB1IR,2C B 1IR$2p n C B 1IR,2C B 1IR$2p
Age (y)
a 318 72 [26–96] 74 [35–89] 0.14
a 321 72 [26–93] 72 [35–96] 0.49
a
Gender
Males 175 107 (61%) 68 (39%) 0.91
b 178 104 (58%) 74 (42%) 0.43
b
Females 143 86 (60%) 57 (40%) 143 77 (54%) 66 (46%)
Site
Right colon 92 57 (62%) 35 (38%) 0.40
c 95 48 (51%) 47 (49%) 0.22
c
Left colon 136 77 (57%) 59 (43%) 135 74 (55%) 61 (45%)
Rectum 87 57 (66%) 30 (34%) 87 55 (63%) 32 (37%)
Disease stage
I 40 27 (68%)
d 13 (33%)
d 0.31
c 40 23 (58%)
d 17 (43%)
d 0.57
c
II 123 74 (60%) 49 (40%) 125 74 (59%) 51 (41%)
III 59 30 (51%) 29 (49%) 60 29 (48%) 31 (52%)
IV 89 57 (64%) 32 (36%) 89 49 (55%) 40 (45%)
Tumour grade
w-m 170 116 (68%) 54 (32%) 0.0052
b 171 113 (66%) 58 (34%) 0.0001
b
m-p 143 75 (52%) 68 (48%) 145 64 (44%) 81 (56%)
Tumour type
Mucinous 41 26 (63%) 15 (37%) 0.86
b 42 20 (48%) 22 (52%) 0.24
b
Non- mucinous 273 165 (60%) 108 (40%) 275 159 (58%) 116 (42%)
Lymphocytes (at TF)
Low no. 168 99 (59%) 69 (41%) 0.64
b 171 88 (51%) 83 (49%) 0.069
b
High no. 145 90 (62%) 55 (38%) 145 90 (62%) 55 (38%)
Buds (at TF)
None 20 11 (55%) 9 (45%) 0.66
c 20 8 (40%) 12 (60%) 0.054
c
1–9 132 83 (63%) 49 (37%) 133 85 (64%) 48 (36%)
10–19 79 45 (57%) 34 (43%) 79 38 (48%) 41 (52%)
$20 75 49 (65%) 26 (35%) 78 46 (59%) 32 (41%)
CIMP status
Negative 173 106 (61%) 67 (39%) 0.83
c 174 99 (57%) 75 (43%) 0.85
c
Low 128 78 (61%) 50 (39%) 129 74 (57%) 55 (43%)
High 15 8 (53%) 7 (47%) 16 8 (50%) 8 (50%)
Abbreviation: TF, tumour front; CIMP, CpG island methylator phenotype. w-m, well/well-moderately differentiated, m-p, , moderate-poor/poorly differentiated.
aData for age is given as medians with range, and the p value was from a Mann-Whitney U-test.
bp values determined by Fisher’s exact test.
cp values determined by x
2 test.
dThe rounding up of the % (e.g. 67.5% R 68%) gives the sum total of 101% for the tumour centre and front data.
doi:10.1371/journal.pone.0023003.t001
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diagnosed with stage I colorectal cancer (where the tumour has
only infiltrated the submucosal layer of the colon or rectum and
has not spread to the lymph nodes or other organs) who died as a
result of their cancer during the follow-up period, precluding
analysis of the influence of CB1IR upon disease-specific outcome
in this patient group. In the case of the tumour front CB1IR, the
significant effect upon tumour outcome in the stage II patients was
also seen, but not in the stage IV patients (Fig. 4 and data not
shown, respectively). In the stage II cases, the 5 year probabilities
of event-free survival were: 8565 and 6668%; tumour interior,
8664% and 6368% for the CB1IR,2 and CB1IR$2 groups,
respectively. It can be noted that some of the stage II cases died
within one month of surgery. However, when these cases were
excluded, the significant contribution of CB1IR to the disease-
specific outcome was retained (data not shown). Upon further
subdivision of the stage II cases according to cancer site, a
significant contribution of both tumour centre and front CB1IR
upon disease-specific survival was seen for the rectal cancers, but
not for the colon cancers, although the direction (i.e. poorer
survival for a high CB1IR) was the same. It is important to note,
however, that interpretation of results with these subgroups are
limited by a low power and are not supported by the Cox analyses
(see below).
The fact that in the MSS patients the CB1IR is associated with
the tumour histological grade at surgery may of course mean that
the association described above is simply a reflection of the
influence of the tumour histological grade upon disease outcome.
This possibility was investigated using multivariate Cox propor-
tional hazards regression analyses (Table 2), where it was found
that the tumour histological grade provided additive prognostic
information to that seen with the tumour centre CB1IR when the
disease stage was also included as a parameter. In contrast, the
tumour front CB1IR parameter lost significance. However, when
the incidence of buds at the tumour front was also included (in
itself a prognostic factor), the influence of the tumour histological
grade upon disease outcome was reduced, whereas the influence of
both tumour center and front CB1IR was significant (Table 2).
These data would suggest that the prognostic significance of the
tumour centre and possibly also tumour front CB1IR is not
secondary to its association with the tumour histological grade.
Further analysis indicated that the prognostic significance of
CB1IR remained when the CIMP status, gender and tumour
region were included in the multivariate analysis (tumour centre,
Exp(B) 1.77 [95% CL 1.16–2.72, p,0.01; tumour front Exp(B)
1.67 [95% CL 1.11–2.50] p,0.05).
For the MSI cases, no conclusions could be drawn as to whether
CB1IR impacted upon disease-specific survival in stage II cases,
simply because of the 32 cases that fell into this category (after
exclusion of cases receiving radiotherapy prior to surgery), only
one died of the cancer during the follow-up period.
Discussion
The present study was motivated by data from both cultured
cells and patient samples suggesting that a dysfunctional
endocannabinoid signalling system is involved either in the
pathogenesis and/or as a consequence of colorectal cancer
[13,14,17,21,22]. At the outset it is worth commenting upon the
fact that both cell surface and cytoplasmic CB1 receptors were
scored. CB1 receptors are often regarded as cell surface
receptors, but it is well established in many cells and tissues
that they have been found intracellularly [34–37], as would be
expected for receptors that internalise following sustained
agonist stimulation [38,39]. It has been suggested that these
intracellular receptors are active and couple to extracellular
signal-regulated kinase [35], although other authors have not
seen intracellular co-localisation of CB1 receptors with Ga
subunits [39]. Naturally-occurring ligands for CB1 receptors are
highly lipophilic, and thus the plasma membrane is not a barrier
to their cellular penetration. Extracellular signal-regulated
kinase is an important signalling molecule, and has been
implicated in antiproliferative effects of cannabinoids in a
number of different cancer cell lines [40], so it is not
unreasonable (and technically considerably less difficult) to
score the combined intensity from plasma membrane and
intracellular CB1 receptors. There are three main results in from
the study, and these are discussed in turn.
Figure 3. Patients with CIMP-high tumours have CB1IR levels
that are not dependent upon the tumour grade. Panel A, tumour
centre; Panel B, tumour front. The data are grouped according to
tumour histological grade (w-m, well/well-moderately differentiated; m-
p, moderate-poor/poorly differentiated) and the CIMP status. Of the 473
cases scored for tumour centre CB1IR, 389 were classified as MSS, 71 as
MSI and 13 not classified in the data base. The corresponding numbers
for the tumour front CB1IR were 392, 71 and 13, respectively. The p
values are for Fisher’s exact test. The total (i.e. CB1IR,2 and $2)
number of cases is shown enclosed within each bar.
doi:10.1371/journal.pone.0023003.g003
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CB1IR intensities in one third of cases investigated
For both tumour centres and invasive fronts, a gamut of CB1IR
scores from absent (0) to pronounced (3) were seen. Although there
was no significant difference between the CB1IR distribution
patterns for the two regions, one third of the cases had a score for
the tumour invasive front that was different from that for the
corresponding tumour centre CB1IR. One possible explanation
for this difference is that the tumour front is an area of intense
immunological and inflammatory activity [41], and it can be
hypothesised that constituents of the tumour front microenviron-
ment affect the transcription of CB1 receptors in this region. One
Table 2. Cox proportional-hazards regression analyses for microsatellite stable (MSS) cancers; influence of disease stage, tumour
grade and number of tumour front buds.
Tumour centre Tumour front
Variable Cat. value n Exp(B) [95%CL] n Exp(B) [95%CL]
Univariate analyses
CB1IR ,2 (1) 182 1 170 1
$2 (2) 121 1.21 [0.84–1.75]
NS 136 1.36 [0.94–1.95]
{
Bivariate analyses
CB1IR ,2 (1) 182 1 170 1
$2 (2) 121 1.72 [1.18–2.53]** 136 1.45 [1.01–2.09]*
Disease Stage I (1) 40 1 40 1
II (2) 121 2.50 [0.75–8.35]
NS 123 2.67 [0.80–8.86]
NS
III (3) 58 4.08 [1.19–14.0]* 59 4.14 [1.20–14.2]*
IV (4) 84 41.0 [12.7–132]*** 84 38.0 [11.8–122]***
Multivariate analyses
CB1IR ,2 (1) 180 1 166 1
$2 (2) 118 1.60 [1.08–2.37]* 135 1.32 [0.91–1.92]
NS
Disease Stage I (1) 37 1 37 1
II (2) 121 2.29 [0.69–7.63]
NS 123 2.38 [0.72–7.92]
NS
III (3) 57 3.68 [1.07–12.7]* 58 3.66 [1.06–12.6]*
IV (4) 83 35.3 [10.9–114]*** 83 32.4 [10.0–104]***
Tumour grade w-m (1) 162 1 163 1
m-p (2) 136 1.44 [0.98–2.13]
{ 138 1.55 [1.05–2.27]*
Multivariate analyses
CB1IR ,2 (1) 175 1 162 1
$2 (2) 111 1.85 [1.22–2.82]** 128 1.67 [1.12–2.49]*
Disease Stage I (1) 37 1 37 1
II (2) 116 2.61 [0.78–8.71]
NS 118 2.62 [0.79–8.71]
NS
III (3) 55 3.79 [1.10–13.1]* 56 3.82 [1.11–13.2]*
IV (4) 78 41.1 [12.6–134]*** 79 38.2 [11.8–124]***
Tumour grade w-m (1) 157 1 158 1
m-p (2) 129 1.36 [0.92–2.02]
NS 132 1.39 [0.94–2.05]
{
Buds (at TF) None (0) 20 20
1–9 (1) 123 1.49 [0.58–3.82]
NS 124 1.97 [0.76–5.08]
NS
10–19 (2) 73 1.25 [0.48–3.27]
NS 73 1.52 [0.59–3.96]
NS
$20 (3) 70 2.78 [1.08–7.16]* 73 3.54 [1.35–9.31]*
Abbreviations: TF, tumour front; w-m, well/well-moderately differentiated; m-p, , moderate-poor/poorly differentiated; Cat. value, categorical value. Exp(B) refers to the
increase in the odds as a result of an increase in the ‘‘unit’’ (shown in brackets in the categorical value column). Significance levels:
***p,0.001,
**p,0.01,
*p,0.05,
{0.5.p.0.1,
NSp.0.1.
In a separate univariate analysis, the Exp(B) value (with 95% confidence limits) for the differentiation state parameter was 2.08 [1.44–3.00], p,0.001. For a bivariate
analysis with disease stage and differentiation state, the Exp (B) value (with 95% confidence limits) for the differentiation state parameter was 1.60 [1.10–2.33], p,0.05.
The level of significance was retained when no. of TF buds was added as a third parameter. Finally, in multivariate analyses with disease stage, no. of TF buds and CB1IR
score, the Exp(B) value (with 95% confidence limits) for tumour centre and tumour front CB1IR scores were 1.97 [1.31–2.96], p,0.01 and 1.81 [1.23–2.68], p,0.01,
respectively.
doi:10.1371/journal.pone.0023003.t002
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4), given that it can increase CB1 receptor expression [42], and
that both IL-4 and IL-4 receptors are found in colon tumours
[43,44]. It would be clearly of interest to determine whether other
constituents of the tumour microenvironment affect CB1 receptor
transcription.
2. The tumour histological grade is associated with CB1IR
in a manner modulated by the CIMP status
For MSS cases, well/well-moderately differentiated tumours
distribute with the ratio of CB1IR,2:$2 among the cases of
approximately 2:1, whilst the ratio is close to 1:1 for the cases with
moderate-poor/poorly differentiated tumours at surgery. In the
MSI cases, no such difference is seen and the cases have a ratio
near 1:1. MSI cases are characterised by a high incidence of
mutated DNA microsatellite markers as a result of a loss of DNA
mismatch repair, and differ from MSS cases not only in terms of
tumour characteristics and gene expression profiles [45] but also in
the survival rates and responses to chemotherapy [46]. It is thus
perhaps not surprising that the MSS and MSI cases have different
CB1IR distributions. However, a major difference between MSS
and MSI cases are the relative incidences of CIMP-negative, low
and high [32], and our analysis suggests that the CIMP status
rather than the microsatellite stability is a prime determinant of
the association of tumour grade with CB1IR. It is notable that for
all cases with a negative CIMP status and moderate-poorly
differentiated tumours, the relative proportion of cases with
CB1IR$2 is similar to that seen for well/well-moderately and
for moderate-poor/poorly differentiated CIMP-high tumours.
This would suggest that the shift in CB1IR distribution seen with
histological grade is brought about along the same pathway as the
shift seen with CIMP-high, so that the effects are not additive.
With respect to the effects of DNA hypermethylation upon CB1
receptor expression, Wang et al. [21] investigated in a series of 13
cases the methylation status of 39 cytosine and guanine-rich DNA
segments (‘‘CpG islands’’) in the region (2212 to +140) of the start
Figure 4. Influence of CB1IR scores at surgery upon disease-specific survival. Kaplan-Meier plots of the disease-specific survival for the
tumour regions and disease stages shown. Shown in the figures are the number of cases (n) followed by the number who died as a result of the
colorectal cancer ({ca). The x
2 value given in the figures is from the log-rank (Mantel- Cox) test comparing the two curves; **p,0.01, *p,0.05,
{0.05,p,0.1;
NSp.0.1. The corresponding x
2 values for tumour front stages III and IV were 0.24
NS and 1.44
NS, respectively.
doi:10.1371/journal.pone.0023003.g004
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CB1 receptor). These authors found hypermethylation of these
sites in the colorectal tumours, ranging from cases with a single
action at position +108 to cases with hypermethylation in $15
sites. They reported that the hypermethylation resulted in Cnr1
gene silencing [21]. Although their study shows an effect in the
opposite direction to the apparent effect of a CIMP-high score
seen here, it is important to stress that the determination of CIMP
in our study was based on a validated eight gene screening panel
[25] and is thus an indication that the tumours have a high
frequency of hypermethylated genes in general, whereas Wang et
al [21] focused on methylation of sites directly relevant to the Cnr1
gene. It is possible that one or several genes that are commonly
inactivated by hypermethylation in CIMP-high tumours have
downstream effects upon the transcription and/or turnover of the
CB1 receptor, and this produces the results seen here, or
alternatively that the pattern of Cnr1 hypermethylation in
colorectal cancer is rather different from that picked up in the
CIMP screen. In the latter situation, a case with a low level of CB1
promotor methylation but a high CIMP score (or vice versa) would
be classified differently in the two studies, so it is not surprising that
the results are divergent. In future studies, it would clearly be of
interest to investigate Cnr1 hypermethylation in our tissue material,
to be able to distinguish between these alternatives.
3. A high CB1IR is associated with a poorer disease-
specific survival in patients with stage II MSS colorectal
cancer
From the introduction, it might have been expected that a high
CB1 tumour receptor expression would be beneficial to the
patients, whereas the opposite was found to be the case, at least for
the patients with stage II MSS tumours at surgery. To our
knowledge, only three studies have been undertaken to investigate
the prognostic value of CB1IR in solid tumours. In hepatocellular
carcinoma, the 35 cases with an undetectable or faint CB1IR
showed a significantly poorer disease-free survival than the 29
cases with a moderate or intense CB1IR [47]. Interestingly, the
distribution of CB1IR was also associated with histological grade,
with 20/34 of the cases with well/well-moderately differentiated
tumours showing a high CB1IR while only 9/30 cases with
moderate-poor/poorly differentiated tumours showed a high
CB1IR [47]. The other two studies, one in pancreas cancer and
one in prostate cancer, are consistent with the present study. In the
pancreatic cancer study, two cohorts were used. In the first cohort
(n=37), a composite scale of immunoreactive intensity6distribu-
tion was used, and cases with a high score were found to have a
significantly shorter median survival than those with a low score
[48]. The same result was seen in a second cohort (n=53)
measuring CB1 receptor mRNA expression with quantitative RT-
PCR. In the prostate cancer study (conducted in Umea ˚ using the
same antibody as in the present study, albeit a different batch), a
composite score was again used, and the disease-specific survival
was significantly poorer for the 192 cases with a CB1IR equal to or
above the median (15 year probability of event-free survival
5065%) than for the 77 cases with a CB1IR below the median (15
year probability of event-free survival 7867%) [26].
It is of course naı ¨ve to assume that the influence of the CB1IR
score is going to be the same regardless of the cancer in question,
but the present study would suggest that hepatocellular carcinoma,
rather than colorectal cancer, is the ‘‘odd cancer out’’. The
question nevertheless remains as to why a high, rather than a low,
CB1 expression should be associated with a poorer disease-specific
survival. One possible explanation has been furnished by a recent
study using cultured astrocytoma cells transfected with CB1
receptors [49]. In that study, the authors selected clones with
different CB1 receptor expression levels and found that at a low
receptor expression, the receptors coupled primarily to extracel-
lular signal-regulated kinases, and that activation of the CB1
receptors led to apoptosis. In contrast, at a high level of CB1
receptor expression, activation of the receptors led additionally to
the activation of the Akt survival pathway, and cannabinoids only
produced apoptosis when this pathway was inhibited [49]. It is of
course a long way from studies in transfected cells to the situation
in solid tumours, but the postulation that a high CB1 receptor
expression results in the switch from a pro-apoptotic to a
predominantly pro-survival pathway would mean that the local
endocannabinoid tone no longer acts to limit the damaging
influence of the tumour but rather to exacerbate it and thereby
result in a poorer prognosis for the patient. The hepatocellular
carcinoma data [47] can be incorporated into this admittedly
speculative hypothesis by suggesting that the cancers defined as
high CB1IR do not have a sufficiently high level of expression to
trigger the switch in these cells.
A final note concerns the potential of CB1IR as a prognostic
marker to aid treatment decisions in cancer. In prostate cancer,
CB1IR looks to be a very promising marker that provides additive
prognostic information to that supplied by other variables such as
the Gleason score and the tumour stage [27,50]. For colorectal
cancer, the situation is less promising, since prognostic significance
was not across the board, but unmasked in the MSS cases when
the disease stage was also taken into consideration. Nonetheless,
given that patients with stage II colorectal cancers are a patient
group where treatment decisions are difficult and better prognostic
markers are needed [51], the present data warrant further
investigation into the potential usefulness of CB1IR as a prognostic
marker to aid such treatment decisions in stage II MSS colorectal
cancer.
Supporting Information
Figure S1 CB1 receptor immunoreactivity in non-ma-
lignant and adenocarcinoma samples. Panel A, non-
malignant tissue; Panel B adenocarcinoma tissue, both stained
using the antibody batch used in [27]. Objective magnification is
106.
(TIF)
Figure S2 CB1 receptor immunoreactivity in forebrain
samples from wild-type and CB1 receptor knockout
mice. Panels A and B show the immunoreactivity from wild-type
and CB1 receptor knockout mice, respectively. Objective magni-
fication is 1.256. The tiff image from the selected areas was
imported into Adobe Photoshop (version CS4 for the Macintosh)
and the colour histograms were captured. Panels C (wild-type) and
D (CB1 receptor knockout) show immunoreactivity from different
forebrain tissue slides to those in Panels A and B, at a higher
objective magnification (206). The colour histograms are for the
whole images. The paraffin embedded, formalin-fixed mouse
tissue was kindly provided by Drs. Beat Lutz and Giacomo
Mancini, Department of Physiological Chemistry, Johannes
Gutenberg-University Mainz, Germany.
(TIF)
Figure S3 Division of CB1IR scores according to tumour
grade, CIMP status and microsatellite stability screen-
ing status. Panel A, tumour centre; Panel B, tumour front. The
data are grouped according to tumour grade (w-m, well/well-
moderately differentiated; m-p, , moderate-poor/poorly differen-
tiated) and microsatellite stability (MSS, stable; MSI, instable) and
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PLoS ONE | www.plosone.org 9 August 2011 | Volume 6 | Issue 8 | e23003the CIMP status. P values were determined using Fisher’s exact
test. The total (i.e. CB1IR,2 and $2) number of cases is shown
enclosed within each bar.
(TIF)
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